Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $4.58 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• BW LPG Limited (BWLP) Reports Q1 EPS of $0.79
• Lobe Sciences upsizes private placement to $2.16M